Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

136 results about "Cerebellum" patented technology

The cerebellum (Latin for "little brain") is a major feature of the hindbrain of all vertebrates. Although usually smaller than the cerebrum, in some animals such as the mormyrid fishes it may be as large as or even larger. In humans, the cerebellum plays an important role in motor control. It may also be involved in some cognitive functions such as attention and language as well as in regulating fear and pleasure responses, but its movement-related functions are the most solidly established. The human cerebellum does not initiate movement, but contributes to coordination, precision, and accurate timing: it receives input from sensory systems of the spinal cord and from other parts of the brain, and integrates these inputs to fine-tune motor activity. Cerebellar damage produces disorders in fine movement, equilibrium, posture, and motor learning in humans.

Combination of atypical antipsychotics and 5HT-1B receptor antagonists

InactiveUS20050256112A1Reduce morbidityDifferent recognizableNervous disorderMetabolism disorderDiseaseHeadaches
The present invention relates to a pharmaceutical composition for treating, for example, a disorder or condition selected from the group consisting of hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress disorder, avoidant personality disorder, sexual dysfunction, eating disorders, obesity, chemical dependencies, cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's diseases, endocrine disorders, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, Fibromyalgia Syndrome, stress incontinence, Tourette syndrome, trichotillomania, kleptomania, male impotence, cancer, chronic paroxysmal hemicrania and headache in a mammal, preferably a human, comprising (i) an atypical antipsychotic or a pharmaceutically acceptable salt thereof, (ii) a 5-HT1B receptor antagonist or a pharmaceutically acceptable salt thereof, wherein the 5-HT1B receptor antagonist is selected from the group consisting of (A) a compound of the formula I as described in the specification and (B) a compound of the formula II as described in the specification, and optionally (iii) a pharmaceutically acceptable carrier.
Owner:PFIZER INC

Treatment of neurological diseases using adeno-associated virus (AAV) comprising AAV-5 capsid proteins

The present invention relates to methods for treating disorders affecting motor function, such as motor function affected by disease, injury to the brain and / or spinal cord using an adeno-associated virus (AAV) gene therapy vector comprising adeno-associated virus 5 (AAV5) capsid proteins and a gene product of interest flanked by AAV ITRs. In particular, the gene therapy vector of the present invention is administered via injection into the cerebrospinal fluid (CSF), preferably by lumbar injection and / or injection into the cisterna magna.
Owner:UNIQURE IP BV

Application of cerebroside compound

InactiveCN101703515AOvercome the difficulty of not being able to separate and purifyHigh yieldOrganic active ingredientsSugar derivativesCerebellumTherapeutic effect
The invention provides application of a cerebroside compound (cerebroside A and cerebroside B) extracted and prepared from termitomyces in the preparation of medicaments for treating brain injury after cerebral ischemia. Through pharmacological experiments, the invention confirms that the cerebroside compound has significant therapeutic effect on ischemic brain injury, can permeate blood-brain barriers, reduces the area of cerebral infarction caused by cerebral ischemia, alleviates cerebral edema, reduces neuronal cell death, simultaneously promotes the recovery of motor and cognitive function after stroke, and reduces stroke mortality. The invention develops novel medicament use of the cerebroside compound, and provides a novel therapeutic medicament for treating stroke diseases.
Owner:NANJING MEDICAL UNIV +2

Application of total saponins of bacopa monnieri (L.) wettst. in preparation of medicaments for resisting cerebral ischemia

The invention provides an application of total saponins of bacopa monnieri (L.) wettst. in preparation of medicaments for resisting cerebral ischemia. The total saponins of the bacopa monnieri (L.) wettst. mainly comprise the following dammarane type triterpenoid saponin compounds: bacopaside I, bacoside A3, bacopaside II, bacopasaponin cisomer and bacopasaponin C. The invention further provides an application of the bacopaside I in preparation of a medicament for resisting cerebral ischemia. The experimental study shows that the total saponins of the bacopa monnieri (L.) wettst. and the bacopaside I have the effects of improving the behavioral symptoms caused by cerebral ischemia reperfusion injury, reducing the cerebral infarct volume and reducing the cerebral edema caused by cerebral ischemia of a rat. Therefore, the total saponins of the bacopa monnieri (L.) wettst. can be used for preparing the medicaments for preventing and treating cerebral ischemia. The medicaments for preventing and treating the cerebral ischemia are prepared from the total saponins of the bacopa monnieri (L.) wettst. or bacopaside I as the active component and medicinal accessories by adopting a conventional method. The invention further expands the function of the bacopaside I and the total saponins of the bacopa monnieri (L.) wettst. and provides the novel medicaments for preventing and treating the cerebral ischemia. The bacopaside I and the total saponins of the bacopa monnieri (L.) wettst. have high clinical application values.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY

Mechanical arm control method based on RBF neural network

The invention discloses a mechanical arm control method based on an RBF neural network. The method includes the steps of firstly, providing a cognition learning model mechanism of a mechanical arm; secondly, putting forward a behavior cognition model based on cerebellum-basal ganglion and a hybrid learning algorithm; thirdly, establishing a mathematical model for the mechanical arm to autonomouslylearn through the artificial neural network and a reinforcement learning method; fourthly, establishing a mechanical arm imitation experimental model in a Matlab; fifthly, verifying the mechanical arm control method based on the RBF neural network. The method has the advantages that the method is not only suitable for the mechanical arm, but also can be applied to other mechanical fields; the method can be applied to other control fields; the method is more suitable for application, and the workloads of programmers can be greatly reduced; the mechanical arm with the autonomous learning capacity has higher competitiveness in future.
Owner:JILIN UNIV

Cerebellar decellularized regeneration biological scaffold, preparation method and application thereof

Belonging to the field of biological tissue engineering and medical materials, the invention relates to a decellularized cerebellar extracellular matrix regeneration biological scaffold containing multiple neurotrophic factors and a preparation method thereof. As a cerebellum regeneration scaffold material, the natural cerebellar decellularized scaffold adopted by the invention is a three-dimensional network structure, and the spatial configuration conforms to the cerebellar physiological structure spatial configuration. The regeneration biological scaffold and its biomechanical properties are similar to normal cerebellus, and can provide physiologically similar channels for reconstruction of nerve pathways so as to provide correct guidance for growth. The scaffold surface has cell-membrane receptor recognition sites and partially active factors, thus being conducive to adhesion growth of cells and functioning of physiological functions. Engineered seed cells can secrete a variety of neurotrophic / growth factors, also can promote the formation of new extracellular matrixes, and provides regeneration guidance signals. With good biocompatibility, the regeneration biological scaffold can be used for preparation of neural repair preparations for treatment of nerve injuries.
Owner:AFFILIATED HUSN HOSPITAL OF FUDAN UNIV

Intrinsic motivation based self-cognition system for motion balance robot and control method

InactiveCN104992059ASolve self-awareness problemsSolve the "conversion" problemSpecial data processing applicationsRoboticsIntrinsics
The invention discloses an intrinsic motivation based self-cognition system for a motion balance robot and a control method. The system comprises an intrinsic motivation based cognition model composed of behavior generation, behavior evaluation and orientation mechanism; the behavior generation is the formation of a 'perception-motion' loop; the behavior evaluation is the formation of a 'motion-result' loop; and the orientation mechanism is used for connecting the behavior generation with the behavior evaluation. The method comprises the steps that: a cortex-cerebellum system calculates action output amount according to sensory cortex information fed back by an intelligent body; a cortex-striatum system in a basal ganglion obtains an evaluation value by utilizing the sensory cortex information fed back by the intelligent body and motor cortex information calculated by cerebellum; and the cortex-striatum system and the cortex-cerebellum system are subjected to synaptic modification. According to the system and the method, neurophysiology, cognitive psychology and robotology are combined, a cognition mechanism is described and realized in a mathematic mode, and the self-cognition problem of the robot is solved.
Owner:TIANJIN UNIV OF TECH & EDUCATION TEACHER DEV CENT OF CHINA VOCATIONAL TRAINING & GUIDANCE

Cytochrome p450ra1-2 and related proteins

InactiveUS20060115811A1High radioactivityMaintain standardCompound screeningBiocideDiseaseMetabolite
The present invention provides a novel all-trans-RA inducible all-trans-RA metabolizing cytochrome P450, P450RAI-2, that is predominantly expressed in the brain, cerebellum in particular. Human P450RAI-2 show 42% amino acid identity to human P450RAI-1 and when transfected into COS-1 cells causes the rapid conversion of all-trans-RA into more polar metabolites including the inactive products 4-oxo-RA, 4-OH-RA and 18-OH-RA. P450RAI-2, as with P450RAI-1, is also inducible in certain cultured cell lines exposed to all-trans-RA. Methods for and uses of the new polynucleotide, polypeptide, fragments thereof and inhibitors thereof, include the treatment of dermatological disorders and cancer.
Owner:PARTEQ INNOVATIONS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products